menu
    • menu
    [{"orgOrder":0,"company":"Trace Neuroscience","sponsor":"Unlearn","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"UNC13A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Trace Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trace Neuroscience \/ Unlearn","highestDevelopmentStatusID":"5","companyTruncated":"Trace Neuroscience \/ Unlearn"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Fermion Oy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FZ008-145","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Fermion Oy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fermion Oy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fermion Oy \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"IND Enabling","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRx-237-801","moa":"Tau aggregation","graph1":"Neurology","graph2":"IND Enabling","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurodon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurodon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurodon \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"Neurodon \/ National Institute on Aging"},{"orgOrder":0,"company":"Genuv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"MEK1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genuv \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Inapplicable"},{"orgOrder":0,"company":"Genuv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"MEK1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genuv \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Inapplicable"},{"orgOrder":0,"company":"ARScience Bio","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"ARScience Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARScience Bio \/ Coya Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ARScience Bio \/ Coya Therapeutics"},{"orgOrder":0,"company":"MedRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"MedRx \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MedRx \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DNL919","moa":"TREM2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Bioresearch \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Bioresearch \/ Inapplicable"},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PRX123","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Merry Life Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Curcumin Analog","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Merry Life Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merry Life Biomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Merry Life Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Aevisbio","sponsor":"KB investment","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"3,6\u2019-dithiopomalidomide","moa":"TNF-alpha receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aevisbio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevisbio \/ KB investment","highestDevelopmentStatusID":"5","companyTruncated":"Aevisbio \/ KB investment"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EM-036","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuMentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EuMentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VENT-02","moa":"NLRP3","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Brain Trust Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Riluzole","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"Brain Trust Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Brain Trust Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Brain Trust Bio \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ARO-SOD1","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trace Neuroscience","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Trace Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trace Neuroscience \/ Third Rock Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Trace Neuroscience \/ Third Rock Ventures"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"The Sheffield Institute for Translational Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-34712","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience","highestDevelopmentStatusID":"5","companyTruncated":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience"},{"orgOrder":0,"company":"Eikonizo Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"EKZ-102","moa":"HDAC-6","graph1":"Neurology","graph2":"IND Enabling","graph3":"Eikonizo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eikonizo Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Eikonizo Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Georgetown University","sponsor":"KeifeRx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"KFRX03","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Georgetown University \/ KeifeRx","highestDevelopmentStatusID":"5","companyTruncated":"Georgetown University \/ KeifeRx"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PAS-003","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PAS-003","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"APB-102","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apic Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Apic Bio","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"APB-102","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apic Bio \/ Uniqure","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/ Uniqure"},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASHA-624","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"The ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"ASHA-624","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Therapeutics \/ The ALS Association","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ The ALS Association"},{"orgOrder":0,"company":"Leal Therapeutics","sponsor":"Chugai Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"LTX-002","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Leal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leal Therapeutics \/ Chugai Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Leal Therapeutics \/ Chugai Venture Fund"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Neurology","graph2":"IND Enabling","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAla Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmAla Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Neurology","graph2":"IND Enabling","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Egret Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EGT 101","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Egret Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egret Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Egret Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Tenvie Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tenvie Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tenvie Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Tenvie Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pipeline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pipeline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pipeline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pipeline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"TheraVac","sponsor":"Perceiv AI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"TV-301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"TheraVac","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TheraVac \/ Perceiv AI","highestDevelopmentStatusID":"5","companyTruncated":"TheraVac \/ Perceiv AI"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Neurology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"5","companyTruncated":"CAMP4 Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ 5Am Ventures","highestDevelopmentStatusID":"5","companyTruncated":"CAMP4 Therapeutics \/ 5Am Ventures"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Lamotrigine","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OWP Pharmaceuticals \/ Eversana","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Eversana"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LPCN 2101","moa":"GABAA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"UCB Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Neurona Therapeutics \/ UCB Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Neurona Therapeutics \/ UCB Ventures"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-260","moa":"Kainate receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-260","moa":"Kainate receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Pharmaleads","sponsor":"IACTA Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"IC 800","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pharmaleads","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Pharmaleads \/ IACTA Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Pharmaleads \/ IACTA Pharmaceuticals"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SPR301","moa":"GCase85","graph1":"Neurology","graph2":"IND Enabling","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PIC1-dPEG24","moa":"C1 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"ATL-201","moa":"KCNT1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Atalanta Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atalanta Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Atalanta Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"ATL-201","moa":"KCNT1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Atalanta Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atalanta Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Atalanta Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Progentos Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Progentos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Progentos Therapeutics \/ Forbion","highestDevelopmentStatusID":"5","companyTruncated":"Progentos Therapeutics \/ Forbion"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMPT-514","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmPACT Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmPACT Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pheno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PTD802","moa":"GPR17","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pheno Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pheno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CD45-ADC","moa":"CD45","graph1":"Neurology","graph2":"IND Enabling","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"IND Enabling","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Neurology","graph2":"IND Enabling","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"5","companyTruncated":"TG Therapeutics \/ Precision BioSciences"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Enterin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enterin \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enterin \/ Inapplicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Nura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Health \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"IND Enabling","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"4E Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"4ET1103","moa":"MNK receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4E Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4E Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"4E Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"4E Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"4ET1103","moa":"MNK receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4E Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4E Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"4E Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"AnaBios","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"ANB-504","moa":"Dual sodium channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"AnaBios","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaBios \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"AnaBios \/ National Institutes of Health"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vigil Neuroscience \/ Atlas Venture","highestDevelopmentStatusID":"5","companyTruncated":"Vigil Neuroscience \/ Atlas Venture"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"EVT8683","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"PRX019","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATB-352","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AmacaThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AMT-143","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AmacaThera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmacaThera \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmacaThera \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ST-503","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intrance Medical System","sponsor":"Erik Selin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Intrance Medical System","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Intrance Medical System \/ Erik Selin","highestDevelopmentStatusID":"5","companyTruncated":"Intrance Medical System \/ Erik Selin"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Parkinson\u2019s Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Parkinson\u2019s Foundation","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Parkinson\u2019s Foundation"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0005","moa":"IL-6 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"JuvVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Financing","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Serina Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Serina Therapeutics \/ JuvVentures","highestDevelopmentStatusID":"5","companyTruncated":"Serina Therapeutics \/ JuvVentures"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"JuvVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Serina Therapeutics \/ JuvVentures","highestDevelopmentStatusID":"5","companyTruncated":"Serina Therapeutics \/ JuvVentures"},{"orgOrder":0,"company":"Enable Injections","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enable Injections","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Enable Injections \/ Serina Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Enable Injections \/ Serina Therapeutics"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"MTK-458","moa":"PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitokinin \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ AbbVie Inc"},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"MTK-458","moa":"PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitokinin \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ AbbVie Inc"},{"orgOrder":0,"company":"NysnoBio","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"NB001","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"NysnoBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NysnoBio \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"5","companyTruncated":"NysnoBio \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Suven Pharmaceuticals","sponsor":"Right Brain Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"RB-190","moa":"Dopamine receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Suven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suven Pharmaceuticals \/ Right Brain Bio","highestDevelopmentStatusID":"5","companyTruncated":"Suven Pharmaceuticals \/ Right Brain Bio"},{"orgOrder":0,"company":"Osmol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OSM-0205","moa":"IntraCellular calcium","graph1":"Neurology","graph2":"IND Enabling","graph3":"Osmol Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osmol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Osmol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Neurology","graph2":"IND Enabling","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Invitae","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Bioresearch \/ Invitae","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Bioresearch \/ Invitae"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Precision Medicines \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Navega Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"NT-Z001","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Navega Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Charles River Laboratories, Inc \/ Navega Therapeutics"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Neurology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EG 427 \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Inapplicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Neurology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EG 427 \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Inapplicable"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Financing","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Serina Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Serina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Serina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xellsmart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"XS411","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Xellsmart","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Xellsmart \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xellsmart \/ Inapplicable"},{"orgOrder":0,"company":"Nuravax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"AV-1959R","moa":"||Amyloid-beta\/Tau","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuravax \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Nuravax \/ National Institutes of Health"},{"orgOrder":0,"company":"Capsida","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CAP-002","moa":"STXBP1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capsida \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Capsida \/ Inapplicable"},{"orgOrder":0,"company":"Rebel Medicine","sponsor":"Crocker Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"Rebel Medicine","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Rebel Medicine \/ Crocker Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Rebel Medicine \/ Crocker Ventures"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"ORX142","moa":"OX2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Nxera Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Nxera Pharma"}]

    Find FDA Investigational New Drug (IND) Submissions for Neurology

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fermion Oy

                            Finland
                            ChemOutsourcing
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWith Fermion, start the journey of your innovative API.

                            Lead Product(s) : FZ008-145

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fermion Announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA

                            Details : FZ008-145 is a highly selective second-generation Nav1.8 inhibitor, offering powerful, non-addictive pain relief advantages. It is being evaluated in preclinical studies for acute and chronic pain.

                            Product Name : FZ008-145

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 01, 2024

                            Lead Product(s) : FZ008-145

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            fermion

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX142

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Sosei Group Corporation

                            Deal Size : $12.9 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nxera to Receive US$4.8 Million Following Centessa’s Initiation of Development of ORX142

                            Details : ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed by Centessa for the treatment of select neurological and neurodegenerative disorders.

                            Product Name : ORX142

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 04, 2025

                            Lead Product(s) : ORX142

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Sosei Group Corporation

                            Deal Size : $12.9 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rebel Medicine

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Rebel Medicine

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Crocker Ventures

                            Deal Size : $6.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Rebel Medicine Secures Series A and Opens IND for Non-Opioid Pain Therapy

                            Details : The proceeds will fund a Phase 2 clinical trial in bunionectomy patients to assess the safety and efficacy of Alevatrix, a novel, long‑acting formulation of bupivacaine for postoperative pain.

                            Product Name : Alevatrix

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 12, 2025

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Crocker Ventures

                            Deal Size : $6.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Capsida

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Capsida

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAP-002

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Capsida Gets FDA IND Clearance for IV Gene Therapy in STXBP1 Disorders

                            Details : CAP-002 is the first engineered IV-delivered gene therapy that crosses the blood-brain-barrier and detargets the liver and dorsal root ganglia to enter the clinic.

                            Product Name : CAP-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : CAP-002

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nuravax

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Nuravax

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-1959R,AV-1980R

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Duvax Alzheimer's Vaccine Wins $3M NIH Grant for U.S. Clinical Trials

                            Details : The funding aims to advance the clinical development of Duvax, the first dual-target. It is being evaluated for the treatment of Alzheimer Disease.

                            Product Name : Duvax

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 05, 2025

                            Lead Product(s) : AV-1959R,AV-1980R

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xellsmart

                            China arrow
                            APGA Annual Conference
                            Not Confirmed

                            Xellsmart

                            China arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XS411

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            XellSmart's iPSC Cell Therapies for Parkinson’s and ALS Approved for Phase I

                            Details : XS411 is an universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy being developed for the treatment of Parkinson's disease (PD).

                            Product Name : XS411

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : XS411

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Serina Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Serina Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POZ-apomorphine

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Serina Secures $5M to Advance SER-252 for Advanced Parkinson’s Disease

                            Details : The financing aims to advance the clinical development of SER-252 (POZ-apomorphine), which is being evaluated for the treatment of Parkinson disease.

                            Product Name : SER-252

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 08, 2025

                            Lead Product(s) : POZ-apomorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Trace Neuroscience

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Trace Neuroscience

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Unlearn

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Unlearn and Trace Neuroscience Partner to Optimize ALS Trials

                            Details : The partnership will support Trace Neuroscience as the company plans its upcoming Phase 1/2 in ALS, using Unlearn’s Digital Twin Generator for ALS.

                            Product Name : Undislcosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 01, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Unlearn

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Suven Pharmaceuticals

                            India arrow
                            APGA Annual Conference
                            Not Confirmed

                            Suven Pharmaceuticals

                            India arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RB-190

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Right Brain Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Right Brain Bio Signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190

                            Details : The agreement aims for the production of its lead drug candidate, RB-190, targeting the root cause of Parkinson's disease.

                            Product Name : RB-190

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 11, 2025

                            Lead Product(s) : RB-190

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Right Brain Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            NKGen Biotech

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NKGen Announces Administration of First Dose of Troculeucel to FD Patient Under FDA

                            Details : SNK01 (troculeucel) is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, being investigated for frontotemporal dementia.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth